QuidelOrtho Corporation Common Stock (QDEL)
Stock · NASDAQ · Health Care
$12.91as of 10/16/2026
Price chart
Active signals
QDEL Signal Track Record
How signals performed across all stocks →What QDEL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -4.6% | 30% | October 1, 2026 |
| Bollinger Band Breakdown | 29 | -1.4% | 41% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.2% | 24% | January 23, 2026 |
| Bollinger Band Breakout | 15 | -4.5% | 33% | October 6, 2026 |
| Any 20-session window (baseline) | -2.8% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tes…
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Employees
- 6,500
- Website
- www.quidelortho.com/
Fundamentals
- 1-day range
- $13.05$13.5
- Market cap
- $1.11B
- P/E (trailing)
- —
- P/E (forward)
- 9.16
- EPS (trailing)
- $-15.40
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 1.55M
How QuidelOrtho Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
QuidelOrtho Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- QDELQuidelOrtho Corporation Common Stock$12.91▼ 7.19%Market cap $1.11BP/E —$9.92$35.58
- NNNNAnbio Biotechnology Class A Ordinary Shares$3.13▼ 5.15%Market cap $1.40BP/E 46.55$3.52$44.73
- ACHVAchieve Life Sciences Inc. Common Shares$6.38▼ 8.46%Market cap $672.42MP/E —$2.62$8.64
- NTLAIntellia Therapeutics Inc. Common Stock$11.42▲ 0.71%Market cap $1.57BP/E —$7.95$28.25
- TKNOAlpha Teknova Inc. Common Stock$7.08▼ 6.84%Market cap $350.10MP/E —$1.91$9.48
- MYGNMyriad Genetics Inc. Common Stock$3.98▼ 8.51%Market cap $304.17MP/E —$2.74$8.59
- IMDXInsight Molecular Diagnostics Inc. Common Stock$3.01▼ 1.63%Market cap $154.99MP/E —$2.42$8.51
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QDEL QuidelOrtho Corporation Common Stock | $1.11B | — | $12.91 | ▼ 7.19% | $9.92$35.58 |
| NNNN Anbio Biotechnology Class A Ordinary Shares | $1.40B | 46.55 | $3.13 | ▼ 5.15% | $3.52$44.73 |
| ACHV Achieve Life Sciences Inc. Common Shares | $672.42M | — | $6.38 | ▼ 8.46% | $2.62$8.64 |
| NTLA Intellia Therapeutics Inc. Common Stock | $1.57B | — | $11.42 | ▲ 0.71% | $7.95$28.25 |
| TKNO Alpha Teknova Inc. Common Stock | $350.10M | — | $7.08 | ▼ 6.84% | $1.91$9.48 |
| MYGN Myriad Genetics Inc. Common Stock | $304.17M | — | $3.98 | ▼ 8.51% | $2.74$8.59 |
| IMDX Insight Molecular Diagnostics Inc. Common Stock | $154.99M | — | $3.01 | ▼ 1.63% | $2.42$8.51 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- QuidelOrtho: Margins Recover, Cash Does NotSeekingAlpha · 10/7/2026
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor RelationsYahoo · 10/7/2026
- 2 Healthcare Stocks with Impressive Fundamentals and 1 Facing ChallengesYahoo · 9/25/2026
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis TreatmentYahoo · 9/24/2026
- Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To KnowYahoo · 9/23/2026
- Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key PlayersYahoo · 9/16/2026
Insider Activity
Insider Actions →- Bowman Ronald Lee · September 15, 2026 · Option Exercise2.6K
- Bowman Ronald Lee · September 15, 2026 · Tax Withholding921 @ $10.63
- Hanson Bryan Michael · August 15, 2026 · Option Exercise446
- Hanson Bryan Michael · August 15, 2026 · Tax Withholding162 @ $14.3
- Young Micah W · July 15, 2026 · Grant356.6K
- Hanson Bryan Michael · July 1, 2026 · Option Exercise5.8K
- Hanson Bryan Michael · July 1, 2026 · Tax Withholding2.1K @ $18.18
- POLAN MARY LAKE PH D · June 6, 2026 · Grant224
- POLAN MARY LAKE PH D · June 6, 2026 · Grant749
- WIDDER KENNETH J · June 6, 2026 · Option Exercise910
- WIDDER KENNETH J · June 6, 2026 · Grant273
- WIDDER KENNETH J · June 6, 2026 · Grant910
- Michael Edward L. · June 6, 2026 · Option Exercise289
- Michael Edward L. · June 6, 2026 · Option Exercise963
- Michael Edward L. · June 6, 2026 · Grant289
Institutional Ownership
March 31, 2026
- Total shares held
- 77.89M
- Total value held
- $1.18B
- Institutional holders
- 233
- Unknown10.45M
- Unknown6.59M
- Unknown5.63M
- Unknown4.56M
- Unknown3.31M
- Unknown3.12M
- Unknown3.05M
- Unknown3.05M
- Unknown2.86M
- Unknown2.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
QuidelOrtho Reports Q2 2026 Results and New IR Lead
QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.
QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.